Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today>

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.
The Manila Times

Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of ...
Yahoo Finance

Cell Line Development Market to Reach USD 12.56 Billion by 2032, Driven by Rising Demand for Biologics, Gene Therapies, and Biopharmaceutical Innovation – SNS Insider

According to SNS Insider, the global Cell Line Development Market was valued at USD 5.46 billion in 2023 and is projected to reach USD 12.56 billion by 2032, expanding at a CAGR of 9.66% from ...